Artal Group S.A. - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 140 filers reported holding FATE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.61 and the average weighting 0.5%.

Quarter-by-quarter ownership
Artal Group S.A. ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$14,820
-43.5%
2,600,0000.0%0.88%
-39.8%
Q4 2022$26,234
-100.0%
2,600,0000.0%1.46%
-41.1%
Q3 2022$58,266,000
-9.6%
2,600,0000.0%2.49%
-27.7%
Q2 2022$64,428,000
-16.9%
2,600,000
+30.0%
3.44%
+6.0%
Q1 2022$77,540,000
-26.4%
2,000,000
+11.1%
3.25%
+13.6%
Q4 2021$105,318,000
+22.5%
1,800,000
+24.1%
2.86%
+48.6%
Q3 2021$85,942,000
-26.6%
1,450,000
+7.4%
1.92%
-19.1%
Q2 2021$117,167,000
+9.3%
1,350,000
+3.8%
2.38%
+25.6%
Q1 2021$107,185,000
-15.8%
1,300,000
-7.1%
1.89%
-30.7%
Q4 2020$127,302,000
+112.3%
1,400,000
-6.7%
2.73%
+87.8%
Q3 2020$59,955,000
-2.9%
1,500,000
-16.7%
1.46%
-15.8%
Q2 2020$61,758,000
+32.4%
1,800,000
-14.3%
1.73%
-12.3%
Q1 2020$46,641,000
+8.3%
2,100,000
-4.5%
1.97%
+18.5%
Q4 2019$43,054,000
+38.6%
2,200,000
+10.0%
1.66%
+33.6%
Q3 2019$31,060,000
+2.0%
2,000,000
+33.3%
1.24%
+1.1%
Q2 2019$30,450,000
-3.7%
1,500,000
-16.7%
1.23%
-4.6%
Q1 2019$31,626,000
+14.6%
1,800,000
-16.3%
1.29%
+26.3%
Q4 2018$27,585,000
-22.7%
2,150,000
-1.8%
1.02%
+10.1%
Q3 2018$35,675,000
+85.1%
2,190,000
+28.8%
0.93%
+126.3%
Q2 2018$19,278,000
+132.4%
1,700,000
+100.0%
0.41%
+294.2%
Q1 2018$8,296,000850,0000.10%
Other shareholders
FATE THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 3,379,064$7,163,6162.64%
Redmile Group, LLC 13,124,427$27,823,7851.32%
Monaco Asset Management SAM 1,847,944$3,917,6411.16%
Casdin Capital, LLC 2,050,000$4,346,0000.48%
TANG CAPITAL MANAGEMENT LLC 700,000$1,484,0000.21%
GCM Grosvenor Holdings, LLC 495,916$1,051,3420.21%
Nebula Research & Development LLC 163,617$346,8680.18%
Bellevue Group AG 4,851,579$10,285,3470.17%
Bruce & Co., Inc. 200,000$424,0000.14%
XTX Topco Ltd 192,920$408,9900.07%
View complete list of FATE THERAPEUTICS INC shareholders